Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market ...

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...

A federal judge in Texas has upheld the U.S. Food and Drug Administration's decision to remove Novo Nordisk's blockbuster drugs Ozempic and Wegovy from the drug shortage list, rejecting a challenge ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Indian drug companies are preparing to launch low-cost versions of Novo Nordisk’s Wegovy and Ozempic as patents expire in 2026, making weight-loss and diabetes treatment more affordable worldwide.

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its ...

U.S. District Judge Mark Pittman in Fort Worth, Texas, reportedly upheld the U.S. Food and Drug Administration's (FDA) ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

Airfares from Europe to the United States have dropped to rates not seen since before the pandemic, as travellers from Western Europe lead a pullback in travel to the U.S. that is expected to continue ...

Novo Nordisk’s campaign, which aims to speak ‘without filters’ by declaring obesity a disease, has been strongly criticized on social media: ‘It’s indecent’ ...

A new study reveals that bariatric surgery results in significantly greater weight loss compared to popular GLP-1 drugs.